Background: Golimumab is a therapeutic anti-TNF monoclonal antibody approved for use in moderate to severe ulcerative colitis (UC). The PURSUIT trials showed a significant exposure-response relationship of golimumab in UC. Interindividual differences in response to golimumab treatment may be explained in part by interindividual variability in pharmacokinetics. Aims: The aim of this research was to develop and validate an enzyme-linked immunosorbent assay (ELISA) to measure golimumab drug concentrations. Methods: Samples diluted at 1:100 were added to microtiter plates coated with recombinant human TNF-alpha for binding. Mouse anti-human immunoglobulin G1 (HRP-anti h IgG1) was used to detect bound golimumab. Assay performance characteristics were determined according to the European in-vitro diagnostic devices directive 98/79/EC. Results: The measuring range of the assay was determined to be 0.415-22.5 µg/mL, and the limit of detection (LoD) for golimumab measurement in human serum samples was 3.56 ng/mL. Intra-assay variation (n=19) was ≤6.6%, while inter-assay variation (n=11) was ≤5.3%. Linearity testing was performed by analyzing three serially-diluted samples spiked with golimumab; golimumab concentrations measured by the new assay were within 98-129% of the expected concentrations. The assay detected no false-positive signals from the samples of untreated patients. Since TNFalpha was used as a capture reagent, other TNF-alpha blockers were detected. Conclusions: This newly-developed ELISA offers a fast and accurate test with reproducible results. The specificity of the assay could be improved by the use of monoclonal antibodies to golimumab. This ELISA has potential utility in therapeutic drug monitoring of patients receiving golimumab, and additionally in pharmacokinetic and pharmacodynamic studies of the drug.
